| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SLNO | Common Stock | Sale | -$93.5K | -1.42K | -1.26% | $65.97 | 111K | Mar 27, 2025 | Direct | F1, F2, F3 |
| transaction | SLNO | Common Stock | Sale | -$154K | -2.31K | -2.08% | $66.79 | 109K | Mar 27, 2025 | Direct | F1, F3, F4 |
| transaction | SLNO | Common Stock | Sale | -$284K | -4.2K | -3.87% | $67.70 | 104K | Mar 27, 2025 | Direct | F1, F3, F5 |
| transaction | SLNO | Common Stock | Sale | -$380K | -5.52K | -5.29% | $68.79 | 98.9K | Mar 27, 2025 | Direct | F1, F3, F6 |
| transaction | SLNO | Common Stock | Sale | -$223K | -3.2K | -3.24% | $69.84 | 95.7K | Mar 27, 2025 | Direct | F1, F3, F7 |
| transaction | SLNO | Common Stock | Sale | -$23.3K | -329 | -0.34% | $70.73 | 95.3K | Mar 27, 2025 | Direct | F1, F3, F8 |
| transaction | SLNO | Common Stock | Sale | -$34.3K | -478 | -0.5% | $71.74 | 94.8K | Mar 27, 2025 | Direct | F1, F3, F9 |
| transaction | SLNO | Common Stock | Sale | -$5.3K | -73 | -0.08% | $72.64 | 94.8K | Mar 27, 2025 | Direct | F1, F3, F10 |
| transaction | SLNO | Common Stock | Options Exercise | $144K | +6K | +6.33% | $24.00 | 101K | Mar 27, 2025 | Direct | F3, F11 |
| transaction | SLNO | Common Stock | Options Exercise | $110K | +4.4K | +4.37% | $25.05 | 105K | Mar 27, 2025 | Direct | F3, F11 |
| transaction | SLNO | Common Stock | Options Exercise | $24.9K | +4.89K | +4.65% | $5.10 | 110K | Mar 27, 2025 | Direct | F3, F11 |
| transaction | SLNO | Common Stock | Options Exercise | $34.6K | +13.3K | +12.11% | $2.60 | 123K | Mar 27, 2025 | Direct | F3, F11 |
| transaction | SLNO | Common Stock | Options Exercise | $20.1K | +8.33K | +6.75% | $2.41 | 132K | Mar 27, 2025 | Direct | F3, F11 |
| transaction | SLNO | Common Stock | Options Exercise | $185K | +35.2K | +26.71% | $5.25 | 167K | Mar 27, 2025 | Direct | F3, F11 |
| transaction | SLNO | Common Stock | Sale | -$3.07M | -46.2K | -27.69% | $66.39 | 121K | Mar 27, 2025 | Direct | F3, F11 |
| transaction | SLNO | Common Stock | Sale | -$1.67M | -24.8K | -20.53% | $67.47 | 95.9K | Mar 27, 2025 | Direct | F3, F11, F12 |
| transaction | SLNO | Common Stock | Sale | -$1.75M | -25K | -26.05% | $70.18 | 70.9K | Mar 27, 2025 | Direct | F3, F11, F13 |
| transaction | SLNO | Common Stock | Sale | -$1.1M | -15.1K | -21.35% | $72.50 | 55.8K | Mar 27, 2025 | Direct | F3, F11 |
| transaction | SLNO | Common Stock | Options Exercise | $90.4K | +2.69K | +4.82% | $33.60 | 58.5K | Mar 28, 2025 | Direct | F3, F11 |
| transaction | SLNO | Common Stock | Sale | -$229K | -3.39K | -5.8% | $67.46 | 55.1K | Mar 28, 2025 | Direct | F3, F11, F14 |
| transaction | SLNO | Common Stock | Sale | -$849K | -12.3K | -22.37% | $68.92 | 42.8K | Mar 28, 2025 | Direct | F3, F11, F15 |
| transaction | SLNO | Common Stock | Sale | -$643K | -9.25K | -21.64% | $69.52 | 33.5K | Mar 28, 2025 | Direct | F3, F11, F16 |
| transaction | SLNO | Common Stock | Sale | -$198K | -2.69K | -8.03% | $73.60 | 30.8K | Mar 28, 2025 | Direct | F3, F11 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SLNO | Employee stock option (right to buy) | Options Exercise | $0 | -6K | -100% | $0.00 | 0 | Mar 27, 2025 | Common Stock | 6K | $24.00 | Direct | F11, F17 |
| transaction | SLNO | Employee stock option (right to buy) | Options Exercise | $0 | -4.4K | -100% | $0.00 | 0 | Mar 27, 2025 | Common Stock | 4.4K | $25.05 | Direct | F11, F17 |
| transaction | SLNO | Employee stock option (right to buy) | Options Exercise | $0 | -4.89K | -66.66% | $0.00 | 2.45K | Mar 27, 2025 | Common Stock | 4.89K | $5.10 | Direct | F11, F18 |
| transaction | SLNO | Employee stock option (right to buy) | Options Exercise | $0 | -13.3K | -100% | $0.00 | 0 | Mar 27, 2025 | Common Stock | 13.3K | $2.60 | Direct | F11, F17 |
| transaction | SLNO | Employee stock option (right to buy) | Options Exercise | $0 | -8.33K | -41.67% | $0.00 | 11.7K | Mar 27, 2025 | Common Stock | 8.33K | $2.41 | Direct | F11, F19 |
| transaction | SLNO | Employee stock option (right to buy) | Options Exercise | $0 | -35.2K | -41.67% | $0.00 | 49.3K | Mar 27, 2025 | Common Stock | 35.2K | $5.25 | Direct | F11, F20 |
| transaction | SLNO | Employee stock option (right to buy) | Options Exercise | $0 | -2.69K | -12.5% | $0.00 | 18.8K | Mar 28, 2025 | Common Stock | 2.69K | $33.60 | Direct | F11, F21 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). |
| F2 | This transaction was executed in multiple trades at prices ranging from $65.15 to $66.145. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| F3 | Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU. |
| F4 | This transaction was executed in multiple trades at prices ranging from $66.24 to $67.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| F5 | This transaction was executed in multiple trades at prices ranging from $67.24 to $68.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| F6 | This transaction was executed in multiple trades at prices ranging from $68.24 to $69.225. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| F7 | This transaction was executed in multiple trades at prices ranging from $69.24 to $70.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| F8 | This transaction was executed in multiple trades at prices ranging from $70.24 to $71.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| F9 | This transaction was executed in multiple trades at prices ranging from $71.26 to $72.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| F10 | This transaction was executed in multiple trades at prices ranging from $72.31 to $72.80. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| F11 | The option exercises and sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person September 13, 2024 |
| F12 | This transaction was executed in multiple trades at prices ranging from 67.41 to $67.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| F13 | This transaction was executed in multiple trades at prices ranging from $70.00 to $70.25. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| F14 | This transaction was executed in multiple trades at prices ranging from $66.90 to $67.83. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| F15 | This transaction was executed in multiple trades at prices ranging from $68.30 to $69.285. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| F16 | This transaction was executed in multiple trades at prices ranging from $69.33 to $69.675. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| F17 | All of the shares subject to this option are fully vested and exercisable as of the date hereof. |
| F18 | One forty-eighth (1/48th) of the shares subject to the Option vest on the first month anniversary of January 1, 2022 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider through each such date. |
| F19 | One forty-eighth of the shares subject to the option vest on February 1, 2023 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date. |
| F20 | One thirty-sixth of the shares subject to the Option vest on June 26, 2023 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider through each such date. |
| F21 | Twelve and one-half percent (12.5%) of the shares subject to the Option vest upon the date following the acceptance by the US FDA of an NDA submission for DCCR, twelve and one-half percent (12.5%) of the shares subject to the Option vest upon the submission by the Company to the European Medicines Agency European of an MAA for DCCR, and one forty-eighth (1/48th) of the remaining shares subject to the Option vest each month anniversary of January 8, 2021 (the "Vesting Commencement Date") on the same day of the month as the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider through each such date. |
Officer title: Senior Vice President, Regulatory Affairs